Chinese patient demand for intravenous therapy: a preliminary survey

Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 386; p. S61
Main Authors Kan, Jenny, Zhu, Xinxing, Wang, Tieying, Lu, Rongzhu, Spencer, Peter S
Format Journal Article
LanguageEnglish
Published London Elsevier Ltd 01.10.2015
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Jiangsu University and OHSU Foundation Global Health Center Fund.
AbstractList Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Jiangsu University and OHSU Foundation Global Health Center Fund.
Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1-5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund.
Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0.74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1-5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund.
Abstract Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund.
Author Kan, Jenny
Zhu, Xinxing
Lu, Rongzhu
Wang, Tieying
Spencer, Peter S
Author_xml – sequence: 1
  givenname: Jenny
  surname: Kan
  fullname: Kan, Jenny
  organization: Oregon Health & Science University (OHSU), Portland, OR, USA
– sequence: 2
  givenname: Xinxing
  surname: Zhu
  fullname: Zhu, Xinxing
  organization: Qilidian Community Health Service Center, Runzhou, Zhenjiang, Jiangsu Province, China
– sequence: 3
  givenname: Tieying
  surname: Wang
  fullname: Wang, Tieying
  organization: Jiangsu University, Zhenjiang, Jiangsu, China
– sequence: 4
  givenname: Rongzhu
  surname: Lu
  fullname: Lu, Rongzhu
  email: lurz@mail.ujs.edu.cn
  organization: Jiangsu University, Zhenjiang, Jiangsu, China
– sequence: 5
  givenname: Peter S
  surname: Spencer
  fullname: Spencer, Peter S
  email: spencer@ohsu.edu
  organization: Jiangsu University, Zhenjiang, Jiangsu, China
BookMark eNqNkEuLFDEUhYOMYM_oTxAK3IyL0nvzqEorKtI-YcCFCr0LmeQWk7E6VSbVDf3vTXWLQoOMq7s55-Pc75ydxSESY48RniFg8_wroIS6aUVzieopQCN5vb7HFihbWSvZrs_Y4k_kATvP-RYAZANqwd6tbkKkTNVop0BxqjxtbPRVN6QqxCnZHcVhm6vphpId9y8qW42J-rAJ0aZ9lbdpR_uH7H5n-0yPft8L9v3D-2-rT_XVl4-fV2-vaie4XNYaHVzrrtNSWwlWkvMer1sHXqEQHq3tvGo1b1XH0WnheUNWKOHapW4AUVywyyN3TMPPLeXJbEJ21Pc2UhlpsJWN1krIZYk-OYneDtsUy7qS4povNQIvqZfHlEtDzok648JURAzz56E3CGY2bA6GzazPoDIHw2Zd2uqkPaawKVru7L059qi42gVKJrvi3pEPidxk_BDuJLw-Ibg-xOBs_4P2lP--ajI3cITMDFQHwgx49W_Afwz4BXNAvM8
CODEN LANCAO
CitedBy_id crossref_primary_10_2196_12577
crossref_primary_10_1016_j_jhazmat_2024_133787
crossref_primary_10_3390_ijerph20043430
crossref_primary_10_1007_s11096_019_00898_0
crossref_primary_10_1016_j_scitotenv_2018_01_271
crossref_primary_10_3389_fpubh_2021_678785
crossref_primary_10_1007_s11356_017_0745_0
crossref_primary_10_1016_j_chemosphere_2023_138211
crossref_primary_10_1186_s41256_019_0097_z
ContentType Journal Article
Copyright 2015 Elsevier Ltd
Elsevier Ltd
Copyright Elsevier Limited Oct 1, 2015
Copyright_xml – notice: 2015 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright Elsevier Limited Oct 1, 2015
DBID AAYXX
CITATION
3V.
7QL
7QP
7RV
7TK
7U7
7U9
7X7
7XB
88A
88C
88E
88G
88I
8AF
8AO
8C1
8C2
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AN0
ASE
AZQEC
BBNVY
BEC
BENPR
BHPHI
C1K
CCPQU
DWQXO
FPQ
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K6X
K9-
K9.
KB0
KB~
LK8
M0R
M0S
M0T
M1P
M2M
M2O
M2P
M7N
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
S0X
7U1
DOI 10.1016/S0140-6736(15)00642-X
DatabaseName CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Public Health Database
Lancet Titles
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
British Nursing Database (Proquest)
British Nursing Index
ProQuest Central Essentials
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
British Nursing Index (BNI) (1985 to Present)
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
British Nursing Index
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Newsstand Professional
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Healthcare Administration Database
Medical Database
Psychology Database
Research Library
Science Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
SIRS Editorial
Risk Abstracts
DatabaseTitle CrossRef
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
Lancet Titles
elibrary
ProQuest AP Science
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Newsstand Professional
Virology and AIDS Abstracts
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
Toxicology Abstracts
ProQuest Science Journals
British Nursing Index with Full Text
ProQuest Health Management
British Nursing Index
ProQuest Nursing & Allied Health Source
ProQuest Psychology Journals (Alumni)
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest Central (Alumni)
Risk Abstracts
DatabaseTitleList
ProQuest One Psychology

Risk Abstracts

Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-547X
EndPage S61
ExternalDocumentID 3851788631
10_1016_S0140_6736_15_00642_X
S014067361500642X
1_s2_0_S014067361500642X
GeographicLocations China, People's Rep., Guangdong Prov
China, People's Rep., Jiangsu Prov
USA
China, People's Rep., Jiangsu
GeographicLocations_xml – name: China, People's Rep., Jiangsu Prov
– name: China, People's Rep., Jiangsu
– name: USA
– name: China, People's Rep., Guangdong Prov
GroupedDBID ---
--K
--M
.1-
.55
.CO
.FO
.GJ
04C
0R~
123
1B1
1P~
1RT
1~5
29L
3EH
3O-
4.4
41~
457
4G.
53G
5VS
7-5
71M
7RV
7X7
88E
88I
8AF
8AO
8C1
8C2
8FE
8FH
8FI
8FJ
8G5
8WZ
9JM
A6W
AABNK
AAEDT
AAEDW
AAEJM
AAIKJ
AAKAS
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABCQX
ABDBF
ABFNM
ABIVO
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABUWG
ABWVN
ACGFS
ACGOD
ACIEU
ACIUM
ACPRK
ACRLP
ACRPL
ACUHS
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
ADXHL
ADZCM
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AFFNX
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGAPS
AGCQF
AGHFR
AGQPQ
AHHHB
AHMBA
AHQJS
AIGII
AIIUN
AITUG
AJJEV
AJRQY
AJUYK
AKBMS
AKRWK
AKVCP
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AN0
ANZVX
APXCP
AQUVI
ARTTT
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BBNVY
BCU
BEC
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BKOMP
BNPGV
BNQBC
BPHCQ
BVXVI
CCPQU
CS3
D0S
DU5
DWQXO
EAP
EAS
EAU
EAZ
EBC
EBD
EBS
EBU
EFJIC
EFKBS
EGS
EHN
EIHBH
EJD
EMB
EMK
EMOBN
ENC
EO8
EO9
EP2
EP3
EPL
EPS
EPT
ESX
EVS
EWM
EX3
F5P
FD8
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-2
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IHE
J1W
J5H
K-O
K9-
KOM
L7B
LK8
LZ2
M0R
M0T
M1P
M2M
M2O
M2P
M41
M7P
MJL
MO0
MVM
N9A
NAPCQ
O-L
O9-
OD.
OO~
OVD
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PRG
PROAC
PSQYO
PSYQQ
PUEGO
Q~Q
R2-
ROL
RPZ
S0X
SAD
SDG
SEL
SES
SJFOW
SJN
SPCBC
SSH
SSZ
SV3
T5K
TEORI
TH9
TLN
TWZ
UAP
UBE
UHU
UKHRP
UQL
UV1
WOQ
WOW
WUQ
X7M
XAX
XDU
XPP
YYM
YYQ
Z5R
ZGI
ZMT
ZXP
ZY4
~G0
3V.
88A
AACTN
AAYOK
ABTAH
ACRZS
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
M0L
PKN
RIG
SDF
ABLVK
ABYKQ
AHPSJ
AJBFU
NHB
XFK
Y6R
ZA5
AAYXX
AGRNS
CITATION
7QL
7QP
7TK
7U7
7U9
7XB
8FK
ASE
C1K
FPQ
H94
K6X
K9.
KB~
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7U1
ID FETCH-LOGICAL-c3249-81c0b8ff848a40a4ecdd1b7c0d5133d1aafd578275f21c83d26ea353c79860113
IEDL.DBID 7X7
ISSN 0140-6736
IngestDate Fri Jul 11 00:15:03 EDT 2025
Sat Aug 23 13:24:04 EDT 2025
Tue Jul 01 03:16:34 EDT 2025
Thu Apr 24 23:00:39 EDT 2025
Fri Feb 23 02:30:16 EST 2024
Sun Feb 23 10:19:31 EST 2025
Tue Aug 26 16:32:01 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3249-81c0b8ff848a40a4ecdd1b7c0d5133d1aafd578275f21c83d26ea353c79860113
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PQID 1728298102
PQPubID 40246
ParticipantIDs proquest_miscellaneous_1746885349
proquest_journals_1728298102
crossref_citationtrail_10_1016_S0140_6736_15_00642_X
crossref_primary_10_1016_S0140_6736_15_00642_X
elsevier_sciencedirect_doi_10_1016_S0140_6736_15_00642_X
elsevier_clinicalkeyesjournals_1_s2_0_S014067361500642X
elsevier_clinicalkey_doi_10_1016_S0140_6736_15_00642_X
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20151001
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 20151001
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle The Lancet (British edition)
PublicationYear 2015
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
SSID ssj0004605
Score 2.160478
Snippet Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics...
Abstract Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are...
Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given...
SourceID proquest
crossref
elsevier
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage S61
SubjectTerms Amino acids
Antibiotic resistance
Antibiotics
Blood pressure
Global health
Health services
Hospitals
Internal Medicine
Medical personnel
Title Chinese patient demand for intravenous therapy: a preliminary survey
URI https://www.clinicalkey.com/#!/content/1-s2.0-S014067361500642X
https://www.clinicalkey.es/playcontent/1-s2.0-S014067361500642X
https://dx.doi.org/10.1016/S0140-6736(15)00642-X
https://www.proquest.com/docview/1728298102
https://www.proquest.com/docview/1746885349
Volume 386
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NS-QwFA-7I8heRFfF0dkhC3vQQ7Vp0zb1IqurDAvKsir0FtJ8gKB1nKow_73vtWkFGde99ND2l8LLy3u_Ju-DkB_AGJRLrQ5S5XjAy1JhDUgTWBWGLnLg8hUmOJ9fpJNr_rtICr_hVvuwys4mNoba3GvcIz_APkpRLsAfHk0fAuwahaervoXGZ7KEpctQq7MiW5QX2YS4v2bwHFz2N3dZsoeOOQqK93zTGyvduJ6zVbLiOSP92U7yGvlkq69k-dyfiq-TX9gE29aW-iKp1Ng7VRkKfJTe4Obtc1OIlba5VvNDquh0Zm-bfl6zOa2fZs92vkGuz06vTiaB744QaCBBuHenw1I4J7hQPFTcamNYmenQYMsWw5RyBmvVZ4mLmBaxiVKr4iTWWS7gL4zFm2RQ3Vd2i1AXA0-MRFpqZjhwABAzz00W5zqGIXg8JLyTi9S-dDh2sLiVC2LEWCIbccpiSPZ72LStnfERIO2ELrvEUDBlEqz7R8BsEdDWfkHWksk6kmGLRjDwYIQCUvRIzzlaLvE_Hx11eiFfv9Or6ZB87x_DksVzGFVZmG14h6cCaBLPt_89xA75AvwsaWMHR2TwOHuy34ADPZbjRtHhKk7YmCwdn178-fsCoS3_3w
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXVF5ioQUjgQSH0PiRxEGqKtRSbWm3F1ppb8axHQmppMumLdo_xW9kJq9KaKFcek3y2dJ4PPPFngfAa2QMtkyDi1JbqkgVhaUakD4KNo5LUaLLt5TgPDlKxyfq8zSZrsCvPheGwip7m9gYan_m6Ix8k_ooiVyjP9ye_YioaxTdrvYtNFq1OAiLn_jLVm_t7-L6vhFi79PxzjjqugpEDskDnXm5uNBlqZW2KrYqOO95kbnYU6sTz60tPdV4z5JScKelF2mwMpEuyzX-vXCJ496C20ri1qTM9B2-LA-zCam_yhja_DI8fMuTd0QERDT9my_8wys0rm5vDe53HJV9bJXqAayE6iHcmXS38I9gl5puhzqwrigr8-G7rTxD_su-0WHxZVP4lbW5XYsPzLLZPJw2_cPmC1ZfzC_D4jGc3IjcnsBqdVaFp8BKibxU6LRw3CvkHLisKveZzJ3EIZQcgerlYlxXqpw6ZpyaJTFpPDGNOM10BO8H2Kyt1XEdIO2FbvpEVDSdBr3JdcBsGTDUnQGoDTe1MHGLJjDyboIiUg_IjuO03OV_Jl3v9cJczTNsixG8Gl6jiaB7H1sFXG38RqUaaZnKn_17iJdwd3w8OTSH-0cHz-EecsOkjVtch9Xz-UXYQP51XrxolJ7B15veZb8BL-A5Yg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UCsUXqTdcrTqCgj7EzUwmyUQQka5La20RtLBv42QuUKjpdtNW9q_56zwnt4Ks1pe-JvlmYOZcvsycC8ALZAwmZN5GmQkykmVpqAaki7yJ4yACunxDCc77B9nOofw0S2dr8KvPhaGwyt4mNobanVg6Ix9THyVRKPSH49CFRXyZTN_PTyPqIEU3rX07jVZE9vzyJ_6-1e92J7jXL4WYfvy2vRN1HQYii0SCzr9sXKoQlFRGxkZ66xwvcxs7anviuDHBUb33PA2CW5U4kXmTpInNC4V_MjzBcW_AzTzJFemY2uarcjKb8PrL7KHx1-HhK56-JlIgotnf_OIfHqJxe9NNuN3xVfahFbA7sOaru7Cx393I34MJNeD2tWddgVbm_A9TOYZcmB3RwfFFUwSWtXley7fMsPnCHze9xBZLVp8vLvzyPhxey7o9gPXqpPIPgYUEOapQWWm5k8g_cItl4fKksAkOIZMRyH5dtO3KllP3jGO9Ij6Np7pZTj0bwZsBNm_rdlwFyPpF131SKppRjZ7lKmC-CujrzhjUmuta6LhFExg5OEERqQZkx3daHvM_k271cqEv5xlUZATPh9doLugOyFQedxu_kZlCiiaLR_8e4hlsoH7pz7sHe4_hFtLEtA1h3IL1s8W5f4JU7Kx82sg8g-_XrWS_ATW0PZg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chinese+patient+demand+for+intravenous+therapy%3A+a+preliminary+survey&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Kan%2C+Jenny%2C+BS&rft.au=Zhu%2C+Xinxing%2C+MD&rft.au=Wang%2C+Tieying%2C+MD&rft.au=Lu%2C+Rongzhu&rft.date=2015-10-01&rft.issn=0140-6736&rft.volume=386&rft.spage=S61&rft.epage=S61&rft_id=info:doi/10.1016%2FS0140-6736%2815%2900642-X&rft.externalDBID=ECK1-s2.0-S014067361500642X&rft.externalDocID=1_s2_0_S014067361500642X
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673615X00110%2Fcov150h.gif